T
UMORIGENESIS involves the abnormal activation of oncogenes and/or the inactivation of tumor suppressor genes. ~ In a variety of human tumors, paradigms are being developed which postulate sequential and cumulative changes in oncogenes and tumor suppressor genes that eventually result in the malignant phenotype. ~4 The interplay between oncogenes and tumor suppressor genes may itself be of some importance, and recent studies have suggested a complex relationship between the product of some of these genes. 6.22.3 ~ In glioblastoma multiforme, the highest grade of astrocytoma, the most commonly affected oncogene is the epidermal growth factor receptor (EGFR) gene. 5'lz' 27. 35 The EGFR gene is located on chromosome 7 and codes for a transmembrane receptor protein with tyrosine kinase activity. Cytogenetic studies have shown a high frequency of double minutes in glioblastomas multiforrne, which correlates with amplified EGFR genes? In turn, molecular genetic analyses have found EGFR gene amplification in approximately 40% of glioblastomas. ~' 3~ Epidermal growth factor receptor gene amplification appears largely restricted to glioblastomas multiforme, but has occasionally been reported in anaplastic astrocytomas. ~. 35 No correlation has been noted between EGFR gene amplification and histopathologi-cal features, and a correlation of EGFR gene amplification with clinical course has produced varied results/23 To our knowledge, EGFR gene amplification has not been correlated with other molecular genetic changes in gliomas.
Cytogenetic and molecular genetic studies have also drawn attention to loss of specific chromosomal regions in astrocytomas, suggesting the presence of tumor suppressor genes in the lost genetic material.'-'4"~ 3,~ 6-~9,24,2s, 29.3~,32.~4 Genetic loss has involved chromosome 10, the short arm of chromosome 17, and, to lesser extents, portions of chromosomes 9 and 22. In addition, mutations have been found in the p53 gene, a putative tumor suppressor gene on the short arm of chromosome 17.1 ~.,_o.2~ However, the most frequently reported losses in glioblastomas have been on chromosome 10, involving either the entire chromosome, or the long or short arm alone. Such losses have been noted in approximately three-quarters of glioblastomas multiforme and have only rarely been seen in anaplastic astrocytomas2 ' 35 No correlation has been made between loss of chromosome 10 and histopathological features. However, there has been a suggestion that tumors that have lost chromosome 10 may represent a different subset from those that show mutations in the p53 gene, and that these differences may result in clinically different courses. ~
The relatively high frequencies of EGFR gene amplification and loss of portions of chromosome 10 in glioblastoma multiforme raise the question of whether these two genetic events are related. Such a relationship may indicate an interplay between the activated oncogene and the inactivated tumor suppressor gene or genes. To evaluate the presence and frequency of EGFR gene amplification and loss of chromosome 10 in a large series of glial tumors of varying histopathological grades and to evaluate the relationship between EGFR gene amplification and loss of chromosome 10, we examined 106 gliomas from 100 patients with Southern blot analysis. All tumors were analyzed for both EGFR gene amplification and loss of heterozygosity with restriction fragment length polymorphisms (RFLP's) on the long and the short arms of chromosome 10.
Materials and Methods

Human Tissue Samples
Samples of tumors were obtained from patients undergoing biopsy at the Massachusetts General Hospital, Boston, and the Universit~itspital, Ztirieh. Three tumors were obtained at autopsy, one (Case 80) at the Massachusetts General Hospital and two (Cases 324 and 438) at the Universit~itspital. Of the 106 tumors, 91 were primary lesions removed prior to radiation therapy and six (Cases 226, 316, 338, 406, 424, and 438) were recurrent lesions previously treated with radiation therapy. Six additional recurrent tumors (Cases 78, 90, 94, 104, 156, and 356) were removed prior to irradiation. Cases 92, 310, and 344 were consecutive recurrent lesions (not irradiated) from a 32-year-old man; the primary tumor was not available for genetic study. Tumor tissues were snap-frozen in liquid nitrogen and stored at -80~ Constitutional deoxyribonucleic acid (DNA) was obtained from peripheral blood of patients undergoing biopsy and from the cerebellar tissue of patients at autopsy.
Histopathological Evaluation
Histopathological sections of all tumors were evaluated by two neuropathologists (D.N.L. and O.D.W.). Tumors were classified and graded according to the World Health Organization guidelines. 2<36 Adult supratentorial astrocytomas were separated into astrocytoma (grade lI), anaplastic astrocytoma (grade III), or glioblastoma multiforme (grade IV). The presence of necrosis was used as the major criterion to distinguish anaplastic astrocytoma and glioblastoma multiforme. 9'~ Histopathological evaluation of the 106 gliomas revealed 58 glioblastomas, 14 anaplastic astrocytomas, five astrocytomas, nine pilocytic astrocytomas, seven mixed gliomas, six oligodendrogliomas, two ependymomas, one subependymoma, one subependymal giant-cell astrocytoma, and three gangliogliomas. Because of their prominent glial components, gangliogliomas were included in the study.
Extraction of DNA and Southern Blot Analysis
Frozen sections were prepared from the tissue samples chosen for DNA extraction. Adjacent tissue without neoplastic change was trimmed. High-molecular-weight DNA from tumor and reference tissue was obtained as previously described ~3 and resuspended in Tris/ethylenediamine tetra-acetic acid to a concentration of 500 ug/ml. Approximately 5 ug of tumor and reference DNA were digested to completion with the appropriate restriction endonucleases (standard conditions as provided by the manufacturer). The DNA was electrophoretically separated in 0.8% agarose gel and transferred to nylon membranes. Prehybridization and hybridization buffers contained 10% sodium dodecyl sulfate (SDS), 7% polyethylene glycol 8000, and 50 ug/ ml salmon sperm DNA for normal hybridization or 50 ug/ml human placental DNA for competitive hybridization conditions. Approximately 20 ng DNA were radiolabeled with 32p-deoxyadenosine triphosphate or 32p-deoxycytidine triphosphate by random oligonucleotide-primed extension. Following overnight incubation, the membranes were washed three times in 0.1% SDS and 0.1 • standard saline citrate at 65"C. Autoradiography was performed on x-ray film using intensifying screens. Membranes were stripped by washing in double-distilled H20 for 2 hours at 65~ and rehybridized to other DNA probes.
DNA Probes and RFLP Analysis
We used a panel of five DNA probes to chromosome 10: two for the short arm (pTBQ7 (D10S28) and a probe for the fibronectin receptor/3 (FNR/3) chain) and three for the long arm (pEFD75 (D10S25), pTB10.163 (D10S22), and 5-1 (DIOS1)). 2~ The following combinations of DNA markers and restriction enzymes were used: pE7 (EGFR) and Bgl II; pTBQ7 (D10S28) and Taq I or Pvu II; pEFD75 (D10S25) and Rsa I or Taq I; pTBI0.163 (D10S22) and Msp I; 5-1 (D10SI) and Taq I; FNRj3 and Hinf I. The RFLP analysis was performed as described elsewhere.~3
Epidermal Growth Factor Receptor Gene Amplification
The EGFR gene amplification was assessed in Bgl IIdigested DNA by Southern blotting using probe pE7. The signal intensity of tumor DNA, hybridized to EGFR gene probe pE7, was compared with constitutional DNA. Serial dilutions and densitometry were performed to assay the degree of amplification. Amplification in tumor DNA was defined as a level greater than five times that of constitutional DNA.
Statistical A nalysis
For statistical analysis of the correlation for two independent variables, the Fisher exact test was applied. Tumors of the same histopathologieal grade from the same patient were included only once.
Results
Glioblastoma Multiforme
The results for the glioblastomas multiforme are displayed in Table 1 , and representative data are illustrated in Figs. l and 2. Of the 53 glioblastomas from different patients, 20 (38%) displayed EGFR gene amplification. Amplification varied from 10-to 100-fold. All of these tumors with EGFR gene amplification also showed loss of heterozygosity on chromosome 10 (LOH 10), while only 18 (55%) of the 33 tumors from different patients without EGFR gene amplification showed such a loss (p < 0.001). In all patients with EGFR gene amplification, all informative markers on chromosome 10 revealed loss of one allele, suggesting the complete loss of one chromosome 10.
Of these 53 glioblastomas multiforme from separate patients, 38 (72%) displayed LOH 10. Among the 38 tumors, 26 were informative on both the long and short arms of chromosome 10; 21 (81%) of these lost genetic material on both the long and short arms, three (12%) only on the long arm, and two (7%) only on the short arm. The remaining 12 patients exhibited loss of material on the short arm of chromosome 10, but data were not informative for markers on the long arm.
Of the 58 total glioblastoma multiforme specimens examined, five were biopsy samples (Cases 310, 338, 344, 406, and 424) obtained later from four patients already examined in the study, and were excluded from the above statistics. Three patients with recurrences (Cases 422 and 424; 336 and 338; 92, 310, and 344) showed EGFR gene amplification and loss of heterozygosity both in the initial tumor and in the sequential specimens. Among these three patients, the EGFR gene copy number did not change between the initially examined and recurrent tumors. One patient (Cases 404 and 406) also showed LOH 10 in the initial and recurrent tumor, but did not exhibit EGFR gene amplification in either. 
* WHO = diagnosis and histopathological grade based on the World Health Organization classification of brain tumors; 36 GBM = glioblastoma multiforme; r = recurrence; x = postradiation; AA = anaplastic astrocytoma; A = astrocytoma; PA = pilocytic astrocytoma; TS = subependymal giant-cell astrocytoma (tuberous sclerosis); O = oligodendroglioma; MG = mixed glioma (oligo-astrocytoma); E = ependymoma; SE = subependymoma; GG = ganglioglioma; amp = amplification; na = no amplification; LOH = loss of heterozygosity; n = normal; --= noninformative; blank space indicates data not available. 
Anaplaslic Astrocytoma
None of the 14 anaplastic astrocytomas showed EGFR gene amplification (Table 1) . Eight anaplastic astrocytomas were informative for markers on both the long and short arms of chromosome 10, two only on the short arm, and one only on the long arm. Three cases were studied only with markers for the long arm and data were informative. For all examined loci on chromosome I0, heterozygosity was maintained.
Other Gliomas
Of the five astrocytomas, nine pilocytic astrocytomas, seven mixed gliomas, six oligodendrogliomas, two ependymomas, one subependymoma, one subependyreal giant-cell astrocytoma, and three gangliogliomas, none showed EGFR gene amplification. None of the chromosome 10 probes detected loss of heterozygosity in any of these tumors. The results are presented in Table 1 .
Discussion
We have studied 106 gliomas for loss of heterozygosity on chromosome I0 (LOH 10) and for EGFR gene amplification. Both loss of chromosome 10 and EGFR gene amplification were restricted to glioblastomas multiforme. Among the group of glioblastoma patients, 72% displayed LOH 10 and 38% showed EGFR gene amplification. The remaining 28% had neither LOH 10 nor EGFR gene amplification. Without exception, those glioblastomas multiforme that exhibited EGFR gene amplification had also lost chromosome 10. In all cases with EGFR gene amplification, LOH 10 was observed for all informative loci on both the short and long arms, indicating the absence of one entire chromosome 10.
Loss of chromosome 10 is the most commonly reported genetic abnormality in glioblastomas multiforme. J6-~8.24.25.32.34 Occasionally, it has also been noted in anaplastic astrocytomas. However, the frequency of LOH 10 in glioblastomas has varied in different studies, with reported figures ranging from approximately 60% to 95% of cases. Our study supports the finding that LOH 10 is common in glioblastomas multiforme, affecting approximately three-quarters of this large series. Our findings further highlight the rarity of LOH 10 in anaplastic astrocytomas, since we were unable to document LOH 10 in our series of 14 such tumors. We have also shown that a wide variety of other gliomas do not show LOH 10. While definite tumor suppressor genes have not yet been identified on chromosome 10, the frequent loss of genetic material on chromosome 10 in glioblastomas multiforme suggests the presence of one or more such genes on this chromosome. In this regard, it is of interest to note that three of our cases show loss of heterozygosity only on the long arm while two others show loss only on the short arm of chromosome 10. This may implicate the involvement of more than one tumor suppressor gene on chromosome 10. Alternatively, there may be subtle genetic changes that are beyond the sensitivity of RFLP analysis.
Epidermal growth factor receptor gene amplification is also common in glioblastoma multiforme and has been reported in 40% to 50% of cases. This amplification has also occasionally been noted in anaplastic astrocytoma. TM Our study agrees with these reported data and emphasizes that EGFR gene amplification is usually restricted to glioblastomas multiforme; EGFR gene amplification was not seen in anaplastic astrocytomas or in a wide variety of other gliomas. In cases in which sequential specimens were available for study, the EGFR gene copy number did not increase in recurrent tumors, and one primary tumor without EGFR gene amplification did not show amplification in the recurrent tumor.
Recent investigations have suggested complex interactions between the products of oncogenes and of tumor suppressor genes, 6zz'3~ and a number of human tumors have been studied in which a loss of genetic material and changes in oncogenes appear to be interrelated. For instance, in neuroblastoma, those patients with amplification of the N-rnyc oncogene almost always show loss of a critical region on the short arm of chromosome 1. TM It has been postulated in neuroblastoma that loss of portions of the short arm of chromosome 1 precedes N-myc amplification, which may be under the control of a specific tumor suppressor gene on the short arm. 7'33 In colon carcinoma (the best studied example of genetic tumor progression), sequential changes involving mutation or loss of a tumor suppressor gene on chromosome 5 (FAP), mutation of the K-ras oncogene on chromosome 12, and alterations of tumor suppressor genes on chromosomes 18 (DCC) and 17 (p53) have been demonstrated, and also suggest the interplay between an oncogene and tumor suppressor genes. TM However, it has been argued that, while many of these genetic changes occur in sequential order, the accumulation of multiple genetic abnormalities may be of greater importance than the specific sequence. 14 In our series, all cases with EGFR gene amplification also had LOH 10. This invariable association suggests a relationship between the two genetic events. The presence of 15 cases of glioblastoma multiforme with LOH 10 but without EGFR gene amplification may further imply that the loss of chromosome 10 precedes EGFR gene amplification in glioblastoma tumorigenesis. This scheme is illustrated in Fig. 3 , in which the formation of a glioblastoma is shown to involve the loss of chromosome 10, followed by amplification of the EGFR gene. Presumably, such a genetic progression represents one of a number of possible pathways. In addition, within this proposed pathway, the loss of material on chromosome 10 and the amplification of the EGFR gene may represent only two events in a multistep process; it is likely that other alterations precede these changes, and some follow. Nonetheless, on the basis of our data and in light of the emerging FIG. 3 . Schematic illustration of a hypothetical genetic pathway in glioblastoma tumorigenesis involving sequential loss of heterozygosity of chromosome 10 (LOH 10) and epidermal growth factor receptor gene amplification (EGFR amp).
understanding of the biology of neuroblastoma, 7 it is tempting to speculate that the loss of a tumor suppressor gene or genes on chromosome 10 may allow EGFR gene amplification to occur.
In the context of the various theories of glioblastoma multiforme formation, these sequential genetic changes may be seen from two different viewpoints. If one adheres to the theory that glioblastomas multiforme arise through progression from astrocytomas, then both LOH 10 and EGFR gene amplification must be viewed as late steps in glioblastoma tumorigenesis, occurring close to the transition from anaplastie astrocytoma to glioblastoma multiforrne. Previous reports 24 and studies in our laboratory (data not shown) have indeed hinted that a proportion of lower-grade astrocytomas that have lost portions of the short arm of chromosome 17 may progress to glioblastoma through loss of chromosome 10.
On the other hand, if one believes that some glioblastomas multiforme arise de novo, then the loss of chromosome 10 and amplification of the EGFR gene may be important early in the formation of a subset of glioblastomas. Our data showing equal EGFR gene amplification in primary and recurrent tumors of individual patients may favor this view. To this end, it has been shown in neuroblastomas that N-myc amplification does not increase in recurrent tumors, and is not found in recurrent tumors when the primary lesion lacked N-myc amplification? On the basis of these data, it has been argued that N-myc amplification represents an early step in neuroblastoma formation and/ or may be intrinsic to a specific subset of neuroblastomas. 7 By analogy, those glioblastomas multiforme that show EGFR gene amplification may represent a given subset of glioblastomas, with amplification occurring early in tumorigenesis, before clinical presentation. In this regard, both the loss of chromosome 10 and EGFR gene amplification may be among the initial steps in glioblastoma tumorigenesis. A better understanding of the multistep development of glioblastoma multiforme will require the identification of additional genetic events involved in this process.
